ArticleClinical case reports2026
Rarity to Remission: Complete Response of Primary Breast Diffuse Large B-Cell Lymphoma With Chemoimmunotherapy.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rarity to Remission: Complete Response of Primary Breast Diffuse Large B-Cell Lymphoma With Chemoimmunotherapy.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Non-Hodgkin's lymphoma of the breast is rare, accounting for < 0.5% of breast cancers and ~2% of extranodal lymphomas. It often presents as a painless lump, mimicking carcinoma and complicating diagnosis. Case PresentationWe report a 65-year-old post-menopausal, hypertensive, and diabetic woman with a gradually enlarging left breast mass. Imaging revealed a suspicious lesion. Core biopsy suggested poorly differentiated carcinoma, but immunohistochemistry confirmed diffuse large B-cell lymphoma (DLBCL), activated B-cell subtype, with high Ki-67 (~90%). PET/CT showed localized disease. She received six cycles of CHOP chemotherapy, with rituximab added from the second cycle. Treatment was well tolerated. Follow-up PET/CT and biopsy demonstrated complete metabolic and pathological remission. ConclusionPrimary breast DLBCL is rare and easily misdiagnosed as carcinoma. Immunohistochemistry is therefore crucial for correct diagnosis. R-CHOP chemoimmunotherapy is the cornerstone of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.